Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(3):463–467. doi: 10.1038/bjc.1996.383

Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres.

L G Jørgensen 1, K Osterlind 1, J Genollá 1, S A Gomm 1, J R Hernández 1, P W Johnson 1, J Løber 1, T A Splinter 1, M Szturmowicz 1
PMCID: PMC2074633  PMID: 8695366

Abstract

The influence of pretreatment serum neuron-specific enolase (S-NSE) in addition to more conventional prognostic factors on survival duration in small-cell lung cancer (SCLC) was investigated in 770 patients from nine centres in six countries. The other variables included stage of disease, performance status (PS), age, sex, serum lactate dehydrogenase (S-LDH), serum alkaline phosphatase (S-AP), and serum carcinoembryonic antigen (S-CEA). Increased values of S-NSE (> 12.5 micrograms-1 l) were observed in 81% of the patients, whereas S-LDH, S-AP and S-CEA were elevated in only half of the patients or less. Multivariable analysis by Cox's proportional hazard model disclosed S-NSE as the most powerful prognostic factor followed by poor PS and extensive stage disease. If PS was ignored, S-LDH came up as a significant prognostic factor. S-AP, S-CEA, age and sex had no significant influence on the prognosis. The three prognostic factors, S-NSE, PS and stage of disease, enabled establishment of a prognostic index (PI) based on a simple algorithm PI = zNSE + z(stage) + 2zPS. This segregated the patients into four groups with clearly different prognosis. The median survival and 95% confidence intervals of the four groups were: 468 days (540-408), 362 days (405-328), 256 days (270-241) and 125 days (179-58). Based on the present results we recommend S-NSE and PS, in addition to stage, for prognostic stratification in treatment trials on SCLC.

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akoun G. M., Scarna H. M., Milleron B. J., Bénichou M. P., Herman D. P. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest. 1985 Jan;87(1):39–43. doi: 10.1378/chest.87.1.39. [DOI] [PubMed] [Google Scholar]
  2. Carney D. N., Marangos P. J., Ihde D. C., Bunn P. A., Jr, Cohen M. H., Minna J. D., Gazdar A. F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13;1(8272):583–585. doi: 10.1016/s0140-6736(82)91748-2. [DOI] [PubMed] [Google Scholar]
  3. Cerny T., Blair V., Anderson H., Bramwell V., Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Feb 15;39(2):146–149. doi: 10.1002/ijc.2910390204. [DOI] [PubMed] [Google Scholar]
  4. Cohen M. H., Ihde D. C., Bunn P. A., Jr, Fossieck B. E., Jr, Matthews M. J., Shackney S. E., Johnston-Early A., Makuch R., Minna J. D. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep. 1979 Feb;63(2):163–170. [PubMed] [Google Scholar]
  5. Cohen M. H., Makuch R., Johnston-Early A., Ihde D. C., Bunn P. A., Jr, Fossieck B. E., Jr, Minna J. D. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):187–195. [PubMed] [Google Scholar]
  6. Cooper E. H., Splinter T. A., Brown D. A., Muers M. F., Peake M. D., Pearson S. L. Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer. 1985 Sep;52(3):333–338. doi: 10.1038/bjc.1985.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Edmonson J. H., Lagakos S. W., Selawry O. S., Perlia C. P., Bennett J. M., Muggia F. M., Wampler G., Brodovsky H. S., Horton J., Colsky J. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep. 1976 Jul;60(7):925–932. [PubMed] [Google Scholar]
  8. Gomm S. A., Keevil B. G., Thatcher N., Hasleton P. S., Swindell R. S. The value of tumour markers in lung cancer. Br J Cancer. 1988 Dec;58(6):797–804. doi: 10.1038/bjc.1988.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harding M., McAllister J., Hulks G., Vernon D., Monie R., Paul J., Kaye S. B. Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer. 1990 Apr;61(4):605–607. doi: 10.1038/bjc.1990.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ihde D. C., Makuch R. W., Carney D. N., Bunn P. A., Cohen M. H., Matthews M. J., Minna J. D. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis. 1981 May;123(5):500–507. doi: 10.1164/arrd.1981.123.5.500. [DOI] [PubMed] [Google Scholar]
  11. Johnson P. W., Joel S. P., Love S., Butcher M., Pandian M. R., Squires L., Wrigley P. F., Slevin M. L. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer. 1993 Apr;67(4):760–766. doi: 10.1038/bjc.1993.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jørgensen L. G., Osterlind K., Hansen H. H., Cooper E. H. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer. 1988 Dec;58(6):805–807. doi: 10.1038/bjc.1988.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Osterlind K., Andersen P. K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986 Aug;46(8):4189–4194. [PubMed] [Google Scholar]
  15. Rawson N. S., Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990 Apr;61(4):597–604. doi: 10.1038/bjc.1990.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Simon R., Altman D. G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994 Jun;69(6):979–985. doi: 10.1038/bjc.1994.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]
  18. Vincent M. D., Ashley S. E., Smith I. E. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1589–1599. doi: 10.1016/0277-5379(87)90436-6. [DOI] [PubMed] [Google Scholar]
  19. Wolf M., Holle R., Hans K., Drings P., Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991 Jun;63(6):986–992. doi: 10.1038/bjc.1991.215. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES